The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
Till ash do us part. The post Top 12 Wedding Cake strains of all time…
A recent study by the Rowett Institute took a look into the potential value of…
However, as more states and countries have embraced cannabis legalization, an unexpected trend has emerged.…
The potential legalization of cannabis nationwide in the United States presents an opportunity for significant…
Budtenders, help us know what’s good in your state. The post What’s good? Leafly Budtenders’…
Meet the cannabis leaders working to mainstream the plant in New York. Presented by Trends…